Lilly Prepares for Sales Pressures in 2011 to 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Facing a patent cliff, the Indianapolis company affirms faith in its pipeline, emerging markets strategy, and bolt-on deals.
You may also be interested in...
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.